



(51) International Patent Classification:

A61K 31/662 (2006.01) C07F 9/30 (2006.01)

A61P 5/14 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2019/066013

(22) International Filing Date:

12 December 2019 (12.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201811527414.4 13 December 2018 (13.12.2018) CN

(71) Applicant: TERNIS, INC. [US/US]; 1065 E. Hillsdale Blvd, Suite 100, Foster City, California 94404 (US).


(72) Inventors: YU, Shanghai; 1065 E. Hillsdale Blvd, Suite 100, Foster City, California 94404 (US). LI, Ben; 1065 E. Hillsdale Blvd, Suite 100, Foster City, California 94404 (US).

(74) Agent: KUZELKA, Jane et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF



(57) Abstract: The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRA selectivity while maintaining good THRB agonistic activity, thereby improving properties of the finished drug. (I)

